Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Deferred Taxes (2017 - 2023)

Historic Deferred Taxes for Lineage Cell Therapeutics (LCTX) over the last 8 years, with Q1 2023 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Deferred Taxes changed N/A to -$1.8 million in Q1 2023 from the same period last year, while for Dec 2023 it was -$1.8 million, marking a year-over-year change of. This contributed to the annual value of -$1.8 million for FY2023, which is N/A changed from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Deferred Taxes stood at -$1.8 million for Q1 2023.
  • In the past 5 years, Lineage Cell Therapeutics' Deferred Taxes ranged from a high of -$169000.0 in Q2 2021 and a low of -$4.4 million during Q1 2019
  • Over the past 4 years, Lineage Cell Therapeutics' median Deferred Taxes value was -$1.0 million (recorded in 2020), while the average stood at -$1.4 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Deferred Taxes skyrocketed by 7981.84% in 2020 and then plummeted by 40600.0% in 2021.
  • Lineage Cell Therapeutics' Deferred Taxes (Quarter) stood at -$991000.0 in 2019, then dropped by 4.84% to -$1.0 million in 2020, then rose by 2.6% to -$1.0 million in 2021, then tumbled by 78.16% to -$1.8 million in 2023.
  • Its Deferred Taxes was -$1.8 million in Q1 2023, compared to -$1.0 million in Q3 2021 and -$169000.0 in Q2 2021.